RECRUITING

TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a personalized approach to the diagnosis and treatment of tinnitus. The overarching goal of this study is to incorporate advanced technologies to provide an objective, data-driven, personalized approach to the diagnosis of chronic tinnitus. This should lead to a clinically applicable tool that can be widely and easily used.

Official Title

Identification and Validation of a Biomarker for Tinnitus: an Objective Data-driven Personalized Approach to Diagnosis of Chronic Tinnitus - The Tinnitus Detection (TIDE) Project

Quick Facts

Study Start:2024-08-01
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06520865

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * (2) for controls: never experienced tinnitus
  2. * (3) age 18 -70;
  3. * (4) ability to understand and consent to the research;
  4. * (5) ability to participate (hearing ability);
  5. * (6) MoCa Test ≥ 26;
  6. * (7) hyperacusis questionnaire score \< 22
  1. * (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint;
  2. * (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing;
  3. * (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis);
  4. * (4) Meniere's disease or similar syndromes;
  5. * (5) vestibular migraine;
  6. * (6) serious internal, neurological or psychiatric conditions;
  7. * (7) epilepsy or other CNS disorders (brain tumor, encephalitis);
  8. * (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start;
  9. * (9) severe hearing loss - inability to communicate properly in the course of the study;
  10. * (10) one deaf ear;

Contacts and Locations

Study Contact

Berthold Langguth, Prof.
CONTACT
+49 941 941
berthold.langguth@medbo.de
Susanne Staudinger, M.A.
CONTACT
susanne.staudinger@medbo.de

Principal Investigator

Sven Vanneste, Prof.
PRINCIPAL_INVESTIGATOR
Trinnitus College Dublin

Study Locations (Sites)

University of Illinois
Champaign, Illinois, 61820
United States
University of Texas
Austin, Texas, 78712
United States

Collaborators and Investigators

Sponsor: University of Regensburg

  • Sven Vanneste, Prof., PRINCIPAL_INVESTIGATOR, Trinnitus College Dublin

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-01
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2024-08-01
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Tinnitus, Biomarker for Tinnitus

Additional Relevant MeSH Terms

  • Tinnitus